|Janus company joins in Directive Board members the ASEBIO|
|Written by ASEBIO|
|Thursday, 14 July 2011 14:34|
The Spanish Biotechnological Sector Association (ASEBIO) had renewed several key positions including the Presidency, Vice presidency and nine of its Directive Board members.
As Vice presidents, José María Fernández Sousa-Faro, Zeltia´s Groups vice president and Antonio Vallespir, Abengoa Bioenergy´s CEO, will work with the President, Regina Revilla in her 2-year mandate.
The recently named president will work to accomplish better R+D fiscal incentives, introduce the biotechnology as a political government priority, increase ASEBIO´s associative base and promote a better use and industrial biotechnology Development.
Also, ASEBIO´s General Assembly had renewed nine Directive Board committee positions, now held by: Oryzon (Carlos Buesa); Grifols Engineering (Esperanza Guisado); AB-Biotics (Miquel Angel Bonachera); Ingenasa (Carmen Vela); Neuron Biopharma (Javier Velasco); Digna Biotech (Pablo Ortiz); Janus Development (María Isabel Berges); Esteve (Eduard Valentí) and GP Pharm (Alberto Bueno). The rest of the committee positions are held by: Amgen (Jordi Martí); Biópolis (Daniel Ramón); Farmasierra (Tomás Olleros); Cellerix (Eduardo Bravo); Genetrix (Pilar de la Huerta); Genzyme (Fernando Royo); Vivia Biotech (Andrés Ballesteros) and Merck (Santiago Almazán).